All In Biotech

Drug Trial Radar · NCT04925752

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,292 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,292

Actual

Start

Jun 28, 2021

Primary completion

Aug 21, 2024

Study completion Aug 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jun 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Interventions

  • Oral Lenacapavir (LEN)Drug

    Tablets administered orally without regard to food

  • F/TDFDrug

    Tablets administered orally

  • Sub-cutaneous (SC) Lenacapavir (LEN)Drug

    Administered via SC injections

  • Placebo SC LENDrug

    Administered via SC injections

  • PTM F/TDFDrug

    Tablets administered orally

  • PTM Oral LENDrug

    Tablets administered orally

  • F/TAF (for US participants only)Drug

    F/TAF tablets administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Time frame: Incidence Phase Screening Visit (Day 1)
  2. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)Time frame: Up to 149 weeks

Locations

93 sites in 8 countries. Site status is shown where the registry gives one.

  • UAB Sexual Health Research Clinic

    Birmingham, Alabama

  • Loma Linda University Clinical Trial Center Clinic

    Loma Linda, California

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • UCLA CBAM Vine Street Clinic

    Los Angeles, California

  • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)

    Los Angeles, California

  • Mills Clinical Research

    Los Angeles, California

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Los Angeles, California

  • BIOS Clinical Research

    Palm Springs, California

  • UCSD Anti Viral Research Center

    San Diego, California

  • Bridge HIV at the San Francisco Department of Public Health

    San Francisco, California

  • Optimus Medical Group

    San Francisco, California

  • University of Colorado Clinical and Translational Research Centers (CTRC)

    Aurora, Colorado

  • Yale University, School of Medicine

    New Haven, Connecticut

  • Whitman-Walker Institute Inc.

    Washington D.C., District of Columbia

  • Washington Health Institute

    Washington D.C., District of Columbia

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • Gary Richmond, MD, PA

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • CAN Community Health Clinic

    Jacksonville, Florida

  • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami

    Miami, Florida

  • CAN Community Health

    Miami Gardens, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • CAN Community Health

    Sarasota, Florida

  • The Hope Clinic at Emory University

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia

  • RMR Core Center

    Chicago, Illinois

  • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH

    Chicago, Illinois

  • Howard Brown Health Center

    Chicago, Illinois

  • Indiana University Infectious Diseases Research

    Indianapolis, Indiana

  • Baptist Health Lexington

    Lexington, Kentucky

  • Norton Infectious Disease Specialists

    Louisville, Kentucky

  • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center

    New Orleans, Louisiana

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • The Fenway Institute

    Boston, Massachusetts

  • Be Well Medical Center

    Berkley, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Open Arms Healthcare Center

    Jackson, Mississippi

  • KC CARE Health Center

    Kansas City, Missouri

  • St. Michael's Medical Center

    Newark, New Jersey

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.